The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Ghrelin Agonist as a Novel Therapeutic Approach to Alleviate Gut Dysmotility and Levodopa-inhibited Gastric Emptying in PD Models
Objective/Rationale:
Patients with Parkinson’s disease (PD) have altered progression of ingested aliments/liquid from their stomach to the intestine, as well as suffer from constipation, and there is...
-
Therapeutic Pipeline Program, 2015Pharmacokinetics and CNS Distribution of IgG Antibodies: Quantitative Comparison of Blood-brain, Blood-CSF and CSF-brain Relationships After Intranasal and Intravascular Dosing
Study Rationale:
Immunotherapy using antibodies (large proteins) directed against alpha-synuclein is a promising, potentially disease-modifying treatment approach for... -
Research Grant, 2015Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program
Promising Outcomes of Original Grant:
Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify... -
Therapeutic Pipeline Program, 2015The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease
Study Rationale:
Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this... -
Therapeutic Pipeline Program, 2015RQ-00000010 for Gastroparesis and Constipation in Parkinson’s Disease
Study Rationale:
Constipation and gastroparesis (slow stomach emptying) are common non-motor symptoms of Parkinson’s disease (PD). These symptoms cause troublesome gastrointestinal... -
Therapeutic Pipeline Program, 2015Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease
Study Rationale:
Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinson’s disease (PD). The natural daily rhythm of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.